Top Five Global Medical Device Companies: Performance, Strategies, and Competitive Analysis

The global medical device industry has experienced high growth during the last five years and is expected to continue its growth momentum, reaching approximately $302 billion in 2017 with a CAGR of 6.1% over the next five years.
 
Lucintel, a leading global management consulting and market research firm, has c

onducted a competitive analysis of the global medical devices industry and presents its findings in “Top Five Global Medical Device Companies: Performance, Strategies, and Competitive Analysis.”
 
Medical device market report provides detailed insight into the performance of the top five medical devices companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.
 
The medical device industry is highly fragmented and consists of surgical and infection control devices, general medical devices, cardiovascular, home healthcare, and other devices. North America dominates this industry. In this study, Lucintel thoroughly profile following five medical device companies with detailed competitive assessments:
 

Lucintel’s research indicates that technological advancement, growing population, and increasing aging population is expected to provide opportunities for the industry players. Technology advancement may lead to nanotechnology applications and use of surgical robots as a new segment entering into the medical device industry, and this is further expected to improve the prospects for the device market. India and China are expected to be the driving countries for growth. North America is expected to witness a considerable growth for the medical device industry over the forecast period. The cardiovascular segment represents good growth during the forecast period.
 
This study is intended to provide industry leaders with a concise overview of the world’s top five global medical equipment companies. This discussion is limited to a comparative analysis of the subject companies, their geographic footprints, financial metrics, market performance, marketing and corporate strategies, and SWOT analysis. It excludes the equipment such as orthopedic, in-vitro diagnostic, technical aids, and such other equipment.
 
Medical device market report will save hundreds of hours of your own personal research time and will significantly benefit you in expanding your business opportunities in global medical device companies. In today’s chaotic economy, you need every advantage that you can find to keep ahead in your business.
 
In Lucintel's newest competitive research study on the world's global medical device companies, we thoroughly profile following five medical device companies with detailed competitive assessments:
 

The detailed analysis of each company offers a critical view into key strategic areas, including:
 

To make any investment, business or strategic decisions, you need adequate and timely information. Medical Device Companies Competitive analysis market report fulfills this core need. This is an indispensable reference guide for industry executives who are dealing with medical device companies.

Some of the features of Top Five Global Medical Device Companies: Performance, Strategies, and Competitive Analysis market intelligence report are:
 

 

List of Figures

 

CHAPTER 3. Market Opportunity

Figure 3.1: Supply chain for medical device industry

Figure 3.2: Global medical device industry trend (2006-2011)

Figure 3.3: Global medical device industry regional trend (2006-2011) US $B

Figure 3.4: Global medical device industry regional trend (2006-2011) (%)

Figure 3.5: Global medical device industry segment trend (2006-2011) (%)

Figure 3.6: Global medical device industry segment trend (2006-2011) US $B

Figure 3.7: Global medical device industry market opportunity by region (2011-2017) (%)

Figure 3.8: Global medical device industry market opportunity by segment (2011-2017) (%)

              

CHAPTER 4.Competitive Benchmarking (Financial and Market)

Figure 4.1: Financial benchmarking of top 5 global medical device companies

Figure 4.2: Gross profit and net profit of top 5 players (2011)

Figure 4.3: Financial analysis – growth leadership quadrant (2011)

Figure 4.4: Global market share of top players in medical device industry (2006) (%)

Figure 4.5: Global market share of top players in medical device industry (2011) (%)

Figure 4.6: Market share analysis of top players in medical device industry (2006) (%)

Figure 4.7: Market share analysis of top players in medical device industry (2011) (E) (%) 

Figure 4.8: Global market share analysis of top players in medical device industry (2011) (%)

Figure 4.9: Global medical device industry: 2011 market fragmentation/consolidation 

Figure 4.10: Market value North America: US $B

Figure 4.11: Market value Europe: US $B

Figure 4.12: Market value Asia Pacific: US $B

Figure 4.13: Market value Row: US $B

Figure 4.14: Global medical device companies – 2011 regional revenue trend (US $B)

Figure 4.15: Global medical device companies – 2011 regional revenue trend (%)

Figure 4.16: North American revenue trend for top players 2007-2011 (US $B)

Figure 4.17: Europe revenue trend for top players 2007-2011 (US $B)

Figure 4.18: Asia Pacific revenue trend for top players 2007-2011 (US $B)

Figure 4.19: Row revenue trend for top players 2007-2011 (US $B)

Figure 4.20: Lucintel triad - top 5 major players

 

CHAPTER 5. Company Profile of Johnson & Johnson

Figure 5.1: Johnson & Johnson revenue by business structure 2011

Figure 5.2: Lucintel triad –Johnson & Johnson

Figure 5.3: Financial benchmarking of Johnson & Johnson against top 3 and top 5 industry players’ average

Figure 5.4: Financial benchmarking of Johnson & Johnson against Top 5 best

Figure 5.5: Global industry revenue trend Vs Johnson & Johnson (2007-2011) in US $B

Figure 5.6: Global market share trend for Johnson & Johnson (2007-2011) in (%)

Figure 5.7: North American industry revenue trend Vs Johnson & Johnson 2007-2011 in US $B

Figure 5.8: European industry revenue trend Vs Johnson & Johnson 2007-2011 in US $B

Figure 5.9: APAC industry revenue trend Vs Johnson & Johnson 2007-2011 in US $B

Figure 5.10: ROW industry revenue trend Vs Johnson & Johnson 2007-2011 in US $B

Figure 5.11: North American market share trend for Johnson & Johnson 2007-2011 in (%)

Figure 5.12: European market share trend for Johnson & Johnson 2007-2011 in (%)

Figure 5.13: APAC market share trend for Johnson & Johnson 2007-2011 in (%)

Figure 5.14: ROW market share trend for Johnson & Johnson 2007-2011 in (%)

Figure 5.15: Trend in R&D expenses 2006-2011 in US $B

Figure 5.16: Trend in R&D expenses 2006-2011 in %

Figure 5.17: Comparison of for Johnson & Johnson 2007-2011 expenditure Vs top 3 & top 5 players average- 2011

Figure 5.18: Johnson & Johnson productivity: 2007-2011 in US$ M

Figure 5.19: Johnson & Johnson fixed asset value: 2007-2011 in US$ M

Figure 5.20: Strategic execution

 

CHAPTER 6. Company Profile of Medtronic, Inc.

Figure 6.1: Medtronic, Inc. revenue by business structure 2011

Figure 6.2: Lucintel triad –Medtronic, Inc.

Figure 6.3: Financial benchmarking of Medtronic, Inc. against top 3 and top 5 industry players’ average

Figure 6.4: Financial benchmarking of Medtronic, Inc. against top 5 best

Figure 6.5: Global industry revenue trend Vs Medtronic, Inc.  (2007-2011) in US $B

Figure 6.6: Global market share trend for Medtronic, Inc. (2007-2011) in (%)

Figure 6.7: North American industry revenue trend Vs Medtronic, Inc. 2007-2011 in US $B

Figure 6.8: European industry revenue trend Vs Medtronic, Inc. 2007-2011 in US $B

Figure 6.9: APAC industry revenue trend Vs Medtronic, Inc. 2007-2011 in US $B

Figure 6.10: ROW industry revenue trend Vs Medtronic, Inc. 2007-2011 in US $B

Figure 6.11: North American market share trend for Medtronic, Inc. 2007-2011 in (%)

Figure 6.12: European market share trend for Medtronic, Inc. 2007-2011 in (%)

Figure 6.13: APAC market share trend for Medtronic, Inc. 2007-2011 in (%)

Figure 6.14: ROW market share trend for Medtronic, Inc. 2007-2011 in (%)

Figure 6.15: Trend in R&D expenses 2006-2011 in US $B

Figure 6.16: Trend in R&D expenses 2006-2011 in %

Figure 6.17: Comparison of Medtronic, Inc. R&D expenditure VS top 3 & top 5 players’ average-2011

Figure 6.18: Medtronic, Inc. productivity: 2007-2011 in US $M

Figure 6.19: Medtronic, Inc.  fixed asset value: 2007-2011 in US $M

Figure 6.20: Strategic execution

 

CHAPTER 7. Company Profile of Covidien Plc

Figure 7.1: Covidien Plcrevenue by business structure 2011

Figure 7.2: Lucintel triad - Covidien Plc

Figure 7.3: Financial benchmarking of Covidien Plc against top 3 and top 5 industry    players’ average

Figure 7.4: Financial benchmarking of Covidien Plcagainst Top 5 best

Figure 7.5: Global industry revenue trend VsCovidien Plc (2007-2011) in US $B

Figure 7.6: Global market share trend for Covidien Plc(2007-2011) in (%)

Figure 7.7: North American industry revenue trend Vs Covidien Plc

                   (2007-2011) in US $B

Figure 7.8:  European industry revenue trend Vs Covidien Plc

                   (2007-2011) in US $B

Figure 7.9:  APAC industry revenue trend Vs Covidien Plc (2007-2011) in US $B

Figure 7.10: ROW industry revenue trend Vs Covidien Plc (2007-2011) in US $B

Figure 7.11: North American market share trend for Covidien Plc (2007-2011) in (%)

Figure 7.12: European market share trend for Covidien Plc (2007-2011) in (%)

Figure 7.13: APAC market share trend for Covidien Plc (2007-2011) in (%)

Figure 7.14: ROW market share trend for Covidien Plc (2007-2011) in (%)

Figure 7.15: Trend in R&D expenses (2006-2011) in US $B

Figure 7.16: Trend in R&D expenses (2006-2011) in %

Figure 7.17: Covidien Plc R&D expenditure VS top 3 & top 5 players average- 2011

Figure 7.18: Covidien Plc Company productivity: 2007-2011 in US $M

Figure 7.19: Covidien Plc fixed asset value: 2007-2011 in US $M

Figure 7.20: Strategic execution

 

CHAPTER  8. Company Profile of Boston Scientific Corporation

Figure 8.1: Boston Scientific revenue by business structure 2011

Figure 8.2: Lucintel triad - Boston Scientific

Figure 8.3: Financial benchmarking of Boston Scientific against top 3 and top 5 industry players’ average

Figure 8.4: Financial benchmarking of Boston Scientific against Top 5 best

Figure 8.5: Global industry revenue trend Vs Boston Scientific(2007-2011) in US $B

Figure 8.6: Global market share trend for Boston Scientific(2007-2011) in (%)

Figure 8.7: North American industry revenue trend Vs Boston Scientific

                 (2007-2011) in US $B

Figure 8.8: European industry revenue trend Vs Boston Scientific

                 (2007-2011) in US $B

Figure 8.9: APAC industry revenue trend Vs Boston Scientific (2007-2011) in US $B

Figure 8.10: ROW industry revenue trend Vs Boston Scientific (2007-2011) in US $B

Figure 8.11: North American market share trend for Boston Scientific (2007- 2011) in (%)

Figure 8.12: European market share trend for Boston Scientific (2007- 2011) in (%)

Figure 8.13: APAC market share trend for Boston Scientific (2007- 2011) in (%)

Figure 8.14: ROW market share trend for Boston Scientific (2007- 2011) in (%)

Figure 8.15: Trend in R&D expenses (2006-2011) in US $B

Figure 8.16: Trend in R&D expenses (2006-2011) in %

Figure 8.17: Comparison of Boston Scientific R&D expenditure VS top 3 & top 5 players average- 2011

Figure 8.18Boston Scientific productivity: 2007-2011 in US $M

Figure 8.19: Boston Scientific fixed asset value: 2007-2011 in US $M

Figure 8.20: Strategic execution

 

CHAPTER 9. Company Profile of Abbott Laboratories

Figure 9.1: Abbott Laboratories revenue by business segments 2011

Figure 9.2: Lucintel triad- Abbott Laboratories

Figure 9.3: Financial benchmarking of Abbott Laboratories against top 3 and top 5 industry players’ average

Figure 9.4: Financial benchmarking of Abbott Laboratories against Top 5 best

Figure 9.5: Global industry revenue trend Vs: Abbott Laboratories(2007-2011) in US $B

Figure 9.6: Global market share trend for Abbott Laboratories (2007-2011) in (%)

Figure 9.7: North American industry revenue trend Vs Abbott Laboratories

                  (2007-2011) in US $B

Figure 9.8: European industry revenue trend Vs Abbott Laboratories

                  (2007-2011) in US $B

Figure 9.9: APAC industry revenue trend Vs Abbott Laboratories (2007-2011) in US $B

Figure 9.10: ROW industry revenue trend Vs Abbott Laboratories (2007-2011) in US $B

Figure 9.11: North American market share trend for Abbott Laboratories(2007-2011) in (%)

Figure 9.12: European market share trend for Abbott Laboratories (2007-2011) in (%)

Figure 9.13: APAC market share trend for Abbott Laboratories (2007-2011) in (%)

Figure 9.14: ROW market share trend for Abbott Laboratories (2007-2011) in (%)

Figure 9.15: Trend in R&D expenses (2006-2011) in US $B

Figure 9.16: Trend in R&D expenses (2006-2011) in %

Figure 9.17: Comparison of Abbott Laboratories R&D expenditure VS top 3 & top 5   players average- 2011

Figure 9.18: Abbott Laboratories productivity: 2007-2011 in US $M

Figure 9.19: Abbott Laboratories fixed asset value: 2007-2011 in US $M

Figure 9.20: Strategic execution

 

 

List of Tables

CHAPTER 3. Market Opportunity

Table 3.1: Global medical device industry parameters 2011

Table 3.2: Relative market attractiveness by region

Table 3.3: Growth rate by region (2006-2011)

Table 3.4: Growth rate by region (2006-2011)

 

CHAPTER 4. Competitive Benchmarking (Financial and Market)

Table 4.1: Financial benchmarking of Top 5global medical device companies

Table 4.2: Key financial parameters for Top 5 Global Medical Device

Table 4.3: Regional revenue (in $B)

Table 4.4: Regional revenue (in %)

Table 4.5: Competitors based on markets served

Table 4.6: Lucintel triad - Top 5 major players

 

CHAPTER 5. Company Profile of Johnson & Johnson

Table 5.1: Market served: Johnson & Johnson

Table 5.2: Lucintel triad - Johnson & Johnson

Table 5.3: Financial benchmarking of Johnson & Johnson against best and against Top 3 and top 5 industry players’ average

Table 5.4: Strategic execution – product positioning by segment

Table 5.5: Strategic execution – perceived customer value / quality

Table 5.6: Strategic execution – promotion / communications

Table 5.7: Strategic execution – product distribution by region

 

CHAPTER 6. Company Profile of Medtronic, Inc.

Table 6.1: Market served –Medtronic, Inc.          

Table 6.2: Lucintel triad - Medtronic, Inc.

Table 6.3: Financial benchmarking of Medtronic, Inc. against best and against Top 3 and top 5 industry players’ average

Table 6.4: Strategic execution – product positioning by segment

Table 6.5: Strategic execution – perceived customer value / quality

Table 6.6: Strategic execution – promotion / communications

Table 6.7: Strategic execution – product distribution by region

 

CHAPTER 7. Company Profile of Covidien Plc

Table 7.1: Market served –Covidien Plc

Table 7.2: Lucintel triad - Covidien Plc

Table 7.3: Financial benchmarking of Covidien Plcagainst best and against Top 3 and top 5 industry players’ average

Table 7.4: Strategic execution – product positioning by segment

Table 7.5: Strategic execution – perceived customer value / quality

Table 7.6: Strategic execution – promotion / communications

Table 7.7: Strategic execution – product distribution by region

 

CHAPTER 8. Company Profile of Boston Scientific Corporation

Table 8.1: Market served–Boston Scientific

Table 8.2: Lucintel triad – Boston Scientific

Table 8.3: Financial benchmarking of Boston Scientific against best and against Top 3 and top 5 industry players’ average

Table 8.4: Strategic execution – product positioning by segment

Table 8.5: Strategic execution – perceived customer value / quality

Table 8.6: Strategic execution – promotion / communications

Table 8.7: Strategic execution – product distribution by region

 

CHAPTER 9. Company Profile of Abbott Laboratories 

Table 9.1: Markets served –Abbott Laboratories

Table 9.2: Lucintel triad - Abbott Laboratories

Table 9.3: Financial benchmarking of Abbott Laboratories against best and against Top 3 and top 5 industry players’ average

Table 9.4: Strategic execution – product positioning by segment

Table 9.5: Strategic execution – perceived customer value / quality

Table 9.6: Strategic execution – promotion / communications

Table 9.7: Strategic execution – product distribution by region